Preferentially expressed antigen in melanoma as a novel diagnostic marker differentiating thymic squamous cell carcinoma from thymoma.

Preferentially expressed antigen in melanoma as a novel diagnostic marker differentiating thymic squamous cell carcinoma from thymoma.

Publication date: Jul 23, 2020

Thymic squamous cell carcinoma (TSQCC), accounting for 70-80% of thymic carcinoma cases, is distinct from thymoma. However, differential diagnosis for type B3 thymoma is sometimes challenging, even with established markers for TSQCC, including KIT and CD5, which are expressed in?~?80% of TSQCCs and?~?3% of thymomas. Novel TSQCC-specific markers would facilitate precise diagnosis and optimal treatment. Herein, we found that preferentially expressed antigen in melanoma (PRAME) may be a novel TSQCC-specific diagnostic marker. We comprehensively profiled 770 immune-related mRNAs in 10 patients with TSQCC and two healthy controls, showing that PRAME and KIT were significantly upregulated in TSQCC (adjusted p values?=?0.045 and 0.0011, respectively). We then examined PRAME expression in 17 TSQCCs and 116 thymomas via immunohistochemistry. All 17 (100%) TSQCCs displayed diffuse and strong PRAME expression, whereas eight of 116 (6.8%) thymomas displayed focal and weak expression (p?

Open Access PDF

Concepts Keywords
Accounting Antigen melanoma
Antigen Thymomas
Differential Diagnosis Medical specialties
Immunohistochemistry Branches of biology
KIT Clinical medicine
Melanoma Cancer
MRNAs Clusters of differentiation
Sci PRAME
Squamous Carcinoma Thymus
Thymoma Thymoma
Thymomas Thymic carcinoma
Immunohistochemistry
Squamous cell carcinoma
CD5

Semantics

Type Source Name
disease MESH melanoma
pathway KEGG Melanoma
disease MESH squamous cell carcinoma
disease MESH thymoma
disease MESH diagnosis
drug DRUGBANK Coenzyme M
disease MESH malignancies
disease MESH metastasis
drug DRUGBANK Dextrose unspecified form
disease MESH Pathology
disease MESH recurrence
drug DRUGBANK Tretinoin
pathway KEGG Apoptosis
disease MESH carcinoma
disease MESH adenocarcinomas
disease MESH renal
disease MESH neuroblastoma
disease MESH myxoid liposarcoma
disease MESH osteosarcoma
disease MESH breast cancer
pathway KEGG Breast cancer
disease MESH liposarcoma
drug DRUGBANK Cefaclor
disease MESH growth
drug DRUGBANK Phosphate ion
drug DRUGBANK L-Tyrosine
disease MESH uveal melanoma
drug DRUGBANK Sunitinib
drug DRUGBANK Imatinib
disease MESH thymic cysts
drug DRUGBANK Formaldehyde
drug DRUGBANK Isosorbide Mononitrate
disease MESH epithelial neoplasms
disease MESH Carcinogenesis
drug DRUGBANK Esomeprazole
disease MESH coma
disease MESH synovial sarcoma
pathway KEGG Chronic myeloid leukemia
pathway KEGG Acute myeloid leukemia
disease MESH myelodysplastic syndromes
drug DRUGBANK Lauric Acid
disease MESH leukemia
disease MESH lung cancer
disease MESH Hodgkin lymphoma
disease MESH B cell lymphoma
disease MESH pancreatitis

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *